Zenas BioPharma, Inc. (ZBIO)
NASDAQ: ZBIO · Real-Time Price · USD
26.92
-0.34 (-1.25%)
Oct 12, 2026, 12:25 PM EDT - Market open
Zenas BioPharma Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Cash & Equivalents | 196.58 | 110.64 | 319.74 | 56.86 | 67.21 |
Short-Term Investments | 446.55 | 232.55 | 31.02 | - | - |
Cash & Short-Term Investments | 643.13 | 343.19 | 350.77 | 56.86 | 67.21 |
Cash Growth | 135.34% | -2.16% | 516.93% | -15.40% | - |
Other Receivables | 0.8 | 1.2 | 2 | - | - |
Receivables | 0.8 | 1.2 | 2 | - | - |
Prepaid Expenses | 9.87 | 6.78 | 3.07 | 1.65 | 1.24 |
Restricted Cash | - | - | 0.09 | - | - |
Other Current Assets | - | - | - | 1.3 | - |
Total Current Assets | 653.79 | 351.17 | 355.92 | 59.8 | 68.44 |
Property, Plant & Equipment | 0.84 | 1.39 | 1.19 | 1.01 | 1.8 |
Long-Term Investments | 30.76 | 17.27 | - | - | - |
Long-Term Deferred Charges | 0.49 | 0.71 | - | 1.39 | - |
Other Long-Term Assets | 15.8 | 13.1 | 12.86 | 5.97 | 4.33 |
Total Assets | 701.69 | 383.64 | 369.97 | 68.18 | 74.58 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Accounts Payable | 7.59 | 7.11 | 17.14 | 5.4 | 5.82 |
Accrued Expenses | 57.41 | 54.31 | 39.16 | 17.01 | 19.44 |
Current Portion of Leases | 0.82 | 1.12 | 0.79 | 0.56 | 0.72 |
Current Income Taxes Payable | - | 0.12 | 0.21 | 0.3 | - |
Total Current Liabilities | 65.82 | 62.65 | 57.29 | 23.26 | 25.97 |
Long-Term Debt | 297.02 | - | - | 20.3 | - |
Long-Term Leases | 0.02 | 0.21 | 0.22 | 0.26 | 0.81 |
Other Long-Term Liabilities | 91.74 | 78.64 | - | - | - |
Total Liabilities | 454.59 | 141.5 | 57.51 | 43.82 | 26.78 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Common Stock | 0.01 | 0.01 | 0 | - | 0 |
Additional Paid-In Capital | 1,206 | 1,007 | 699.65 | 4.65 | 1.03 |
Retained Earnings | -957.57 | -765.13 | -387.39 | -230.4 | -193.28 |
Comprehensive Income & Other | -1.14 | -0.06 | 0.19 | 0.04 | -0.04 |
Total Common Equity | 247.1 | 242.14 | 312.46 | -225.72 | -192.29 |
Shareholders' Equity | 247.1 | 242.14 | 312.46 | 24.37 | 47.8 |
Total Liabilities & Equity | 701.69 | 383.64 | 369.97 | 68.18 | 74.58 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Total Debt | 297.86 | 1.33 | 1 | 21.11 | 1.53 |
Net Cash (Debt) | 345.27 | 341.87 | 349.76 | 35.74 | 65.68 |
Net Cash Growth | 26.81% | -2.26% | 878.52% | -45.58% | - |
Net Cash Per Share | 6.45 | 7.64 | 26.50 | 23.34 | 44.02 |
Filing Date Shares Outstanding | 65.18 | 57.36 | 41.8 | 1.58 | 1.55 |
Total Common Shares Outstanding | 63.33 | 54.49 | 41.79 | 1.58 | 1.55 |
Working Capital | 587.98 | 288.52 | 298.63 | 36.55 | 42.48 |
Book Value Per Share | 3.90 | 4.44 | 7.48 | -143.15 | -124.11 |
Tangible Book Value | 247.1 | 242.14 | 312.46 | -225.72 | -192.29 |
Tangible Book Value Per Share | 3.90 | 4.44 | 7.48 | -143.15 | -124.11 |